Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Agenus Shares Rose as Much as 13.5% Today

By Maxx Chatsko - Updated Apr 11, 2019 at 8:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Bill & Melinda Gates Foundation helped to kick-start a manufacturing partnership for the small-cap biopharma.

Editor's note: A previous version of this article misstated the nature of the partnership between Phyton and Agenus, and implied that Phyton manufactures vaccines. The Fool regrets the error.

What happened

Shares of Agenus (AGEN 1.03%) soared over 13% higher today after the company announced it had received a $1 million grant from the Bill & Melinda Gates Foundation to develop a new manufacturing process for QS-21, a product added to various vaccines. To get started, the company also announced a partnership with Phyton Biotech that will leverage the new partner's novel plant-based manufacturing technology.

If successful, the effort could increase the availability of QS-21, reduce its cost, and reduce the environmental impact from current product methods, creating the potential to significantly expand the product's market opportunity.

As of 3:11 p.m. EST on Thursday, the stock had settled to a 10% gain.

Plant seedlings in ascending order.

Image source: Getty Images.

So what

In technical terms, QS-21 is a saponin-based vaccine adjuvant. That means it's extracted from the soapbark tree native to Chile. As is often the case with rare and high-value natural products, the extraction process is not very efficient. That poses a problem as QS-21 finds a use in more and more vaccines, notably the Shingrix shingles vaccine from GlaxoSmithKline and many others under development at the industry leader.

Enter Phyton Biotech. The company's plant cell fermentation (PCF) technology grows plant cell cultures in steel bioreactors -- similar to brewing beer. PCF makes it possible to leverage high-yield, high-efficiency industrial biotechnology processes for manufacturing various pharmaceutical products that are difficult to produce by other means. A plant-based production process is a great fit for manufacturing QS-21.

While industrial plant cell cultures aren't unique to Phyton Biotech, the company is a leader in the niche manufacturing process. It's currently the world's largest producer of taxanes, a class of chemotherapy drugs, and owns significant global manufacturing capacity. 

Now what

That said, while the partnership is potentially great news for ensuring a stable supply of QS-21, the material benefit to Agenus appears limited. In January 2018, it sold the royalty rights to the saponin-based vaccine adjuvant for a quick cash injection of $190 million. It could earn up to $40.4 million in milestone payments based on sales figures this year and next, but the PCF-based platform may not be fully ramped up by then. It can take 12 to 24 months to ramp up a new industrial biotech process -- and this one is still being developed. 

In other words, today's news doesn't really move the needle for long-term investors, although Agenus is making progress developing its pipeline elsewhere.

Check out the latest Agenus earnings call transcript.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Agenus Inc. Stock Quote
Agenus Inc.
$1.96 (1.03%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.